| Literature DB >> 27678382 |
Sophie Caillard1, Camille Becmeur1, Gabriela Gautier-Vargas1, Jerome Olagne1,2, Clotilde Muller1, Noelle Cognard1, Peggy Perrin1, Laura Braun1, Francoise Heibel1, Francois Lefebre3, Veronique Renner4, Christian Gachet4, Bruno Moulin1, Anne Parissiadis4.
Abstract
Donor-specific antibodies (DSA) increase the risk of allograft rejection and graft failure. They may be present before transplant or develop de novo after transplantation. Here, we studied the evolution of preformed DSA and their impact on graft outcome in kidney transplant recipients. Using the Luminex Single Antigen assay, we analyzed the sera on the day of transplantation of 239 patients who received a kidney transplant. Thirty-seven patients (15.5%) had pre-existing DSA detected the day of transplantation. After 5 years, the pre-existing DSA disappeared in 22 patients whereas they persisted in 12. Variables associated with DSA persistence were age <50 years (P = 0.009), a history of previous transplantation (P = 0.039), the presence of class II DSA (P = 0.009), an MFI of preformed DSA >3500 (P < 0.001), and the presence of two or more DSA (P < 0.001). DSA persistence was associated with a higher risk of graft loss and antibody-mediated rejection. Previously undetected preformed DSA are deleterious to graft survival only when they persist after transplantation.Entities:
Keywords: antibody-mediated rejection; donor-specific antibody; graft survival; kidney transplantation
Mesh:
Substances:
Year: 2016 PMID: 27678382 DOI: 10.1111/tri.12864
Source DB: PubMed Journal: Transpl Int ISSN: 0934-0874 Impact factor: 3.782